Trial Information
Nexium Capsules Clinical Experience Investigation
Nexium capsules Clinical Experience Investigation
Inclusion Criteria:
- Patients treated with Nexium for the first time due to gastric
ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease,
Zollinger-Ellison syndrome. Exclusion Criteria: - None
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Number of Adverse Drug Reactions
Outcome Time Frame:
Patients with gastric ulcer, anastomotic ulcer or Zollinger-Ellison syndrome: 8 weeks
Safety Issue:
Yes
Principal Investigator
Shigeru Yoshida, MD
Investigator Role:
Study Director
Investigator Affiliation:
Astrazeneca K.K.
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
D961HC00010
NCT ID:
NCT01434485
Start Date:
September 2011
Completion Date:
December 2013
Related Keywords:
- Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
- gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome, Nexium
- Duodenal Ulcer
- Esophagitis
- Esophagitis, Peptic
- Gastroesophageal Reflux
- Stomach Ulcer
- Ulcer
- Zollinger-Ellison Syndrome
- Gastrinoma